Yunkang Group Limited (HKG:2325)
Hong Kong · Delayed Price · Currency is HKD 0.5200
+0.0100 (1.96%)
Sep 11, 2026, 3:59 PM HKT
Yunkang Group Revenue
Yunkang Group had revenue of 252.76M CNY in the half year ending June 30, 2026, a decrease of -33.47%. This brings the company's revenue in the last twelve months to 540.94M, down -16.15% year-over-year. In the year 2025, Yunkang Group had annual revenue of 601.39M, down -15.52%.
Revenue (ttm)
540.94M CNY
Revenue Growth
-16.15%
P/S Ratio
0.48
Revenue / Employee
536.64K CNY
Employees
1,008
Market Cap
298.53M HKD
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 601.39M | -110.50M | -15.52% |
| Dec 31, 2024 | 711.88M | -179.62M | -20.15% |
| Dec 31, 2023 | 891.50M | -2.86B | -76.27% |
| Dec 31, 2022 | 3.76B | 2.06B | 121.38% |
| Dec 31, 2021 | 1.70B | 496.42M | 41.36% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| WuXi XDC Cayman | 8.02B |
| Adicon Holdings | 3.06B |
| Kindstar Globalgene Technology | 1.10B |
| Mega Genomics | 413.73M |
| Biosino Bio-Technology and Science Incorporation | 196.98M |
| Zhong Ji Longevity Science Group | 150.07M |
| King International Investment | 143.23M |
| Guanze Medical Information Industry (Holding) | 98.16M |